Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America…
Pharmaceuticals, Biotechnology and Life Sciences
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America…
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the…
SANTA ANA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company…
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST Liege, Belgium, September 21,…
Information on the total number of voting rights (denominator) Liege, Belgium, 21 September 2023 – 5:45 pm CEST – Mithra…
Debenture proceeds will provide additional funds and flexibility for growthBOUCHERVILLE, Québec, Sept. 21, 2023 (GLOBE NEWSWIRE) — LSL Pharma Group…
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits…
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ:…
TEMPLE CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Cage-Free Repair announced today that it has released its annual 2023…